ArticleInternational journal of nanomedicine2020
Berberine-Loaded Nanostructured Lipid Carriers Enhance the Treatment of Ulcerative Colitis.
Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Pharmacological effects of berberine on models of ulcerative colitis: A meta-analysis and systematic review of animal studies.Frontiers in pharmacology · 2022Pooled it
- Berberine in Inflammatory Bowel Disease: Integrative Regulation of the Microbiota-Immune-Barrier Axis.International journal of molecular sciences · 2026Review
- Berberine: A Negentropic Modulator for Multi-System Coordination.International journal of molecular sciences · 2026Review
- Berberine in oral diseases: molecular mechanisms and therapeutic implications.Frontiers in pharmacology · 2026Review
- Microbiota-Sensitive Nanocarriers for the Targeted Delivery of Therapeutic Agents into the Gut: Advanced Treatment Strategy for Inflammatory Bowel Disease.Current pharmaceutical design · 2026Review
- Berberine in Bowel Health: Anti-Inflammatory and Gut Microbiota Modulatory Effects.International journal of molecular sciences · 2025Review
- Oral Lipid Nanoparticles for Improving the Efficiency of Drug Delivery Systems in Ulcerative Colitis: Recent Advances and Future Prospects.Pharmaceutics · 2025Review
- In Vitro Evaluation of the Safety and Antineoplastic Effects in Gastrointestinal Tumors of Nanostructured Lipid Carriers Loaded with Berberine.Pharmaceutics · 2025Article
- Crosstalk between neutrophil extracellular traps and gut microbiota in ulcerative colitis: traditional Chinese medicine strategies.Frontiers in cellular and infection microbiology · 2025Review
- Supplementation of Glucosamine Selenium Ameliorates DSS-Induced Chronic Colitis in Mice via Affecting Gut Microbiota, Inhibiting Pyroptosis and Inactivating Chemokine Signaling Pathway.Journal of inflammation research · 2025Article
- Recent Insight into Herbal Bioactives-based Novel Approaches for Chronic Intestinal Inflammatory Disorders Therapy.Current pharmaceutical biotechnology · 2024Review
- Combined ROS Responsive Polydopamine-Coated Berberine Nanoparticles Effective Against Ulcerative Colitis in Mouse Model.International journal of nanomedicine · 2024Article
- Characterization and Pharmacokinetic Assessment of a New Berberine Formulation with Enhanced Absorption In Vitro and in Human Volunteers.Pharmaceutics · 2023Article
- Cell-Membrane-Coated Nanoparticles for Targeted Drug Delivery to the Brain for the Treatment of Neurological Diseases.Pharmaceutics · 2023Review
- Berberine in Sepsis: Effects, Mechanisms, and Therapeutic Strategies.Journal of immunology research · 2023Review
- Article
- β-Caryophyllene Acts as a Ferroptosis Inhibitor to Ameliorate Experimental Colitis.International journal of molecular sciences · 2022Article
- Effect and Mechanism of Pharmaceutical Excipients on Berberine to Alleviate Ulcerative Colitis via Regulating Gut Microbiota.Molecules (Basel, Switzerland) · 2022Article
- Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends.Molecules (Basel, Switzerland) · 2022Review
- Bioactive Loaded Novel Nano-Formulations for Targeted Drug Delivery and Their Therapeutic Potential.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBerberine (BBR), a major ingredient extracted from
methodsBBR-loaded nanostructured lipid carriers (BBR-NLCs) prepared via high-pressure homogenization were evaluated for particle size, zeta potential, drug entrapment efficiency, drug loading, drug release, toxicity, and cellular uptake. The anti-UC activities of free and encapsulated BBR were evaluated in a DSS-induced acute model of UC in mice.
resultsSpherical BBR-NLCs were prepared with a particle size of 63.96± 0.31 nm, a zeta potential of +3.16 ± 0.05 mV, an entrapment efficiency of 101.97±6.34%, and a drug loading of 6.00±0.09%. BBR-NLCs showed excellent biocompatibility in vivo. Cellular uptake experiments showed that BBR-NLCs improved uptake of BBR by RAW 264.7 cells and Caco-2 cells. Oral administration of BBR-NLCs significantly alleviated colitis symptoms (DAI, colon length, spleen swelling, MPO activity) through inhibition of NF-κB nuclear translocation, decreased expression of pro-inflammatory cytokines (IL-1β, IL-6, MMP-9, CX3CR1, COX-2, TERT), and increased expression of the tight junction protein ZO-1.
conclusionBBR-loaded NLCs improved colitis symptoms, which suggested that this may be a novel formulation for treatment of UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.